Skip to content

Celgene, Agios update blood cancer study at ASCO

May 18, 2017

Celgene (CELG) and Agios Pharmaceuticals (AGIO) dropped updated clinical trial results for their targeted blood cancer drug enasidenib into a research abstract for the American Society of Clinical Oncology (ASCO) annual meeting.

The abstract with the new enasidenib data — improved tumor response rate but shorter duration — was made public on Wednesday night, along with all other regular abstracts submitted for the ASCO meeting taking place next month.

Celgene and Agios submitted an application to the FDA seeking approval of enasidenib (also known as AG-221) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) caused by a mutated protein known as IDH2. The FDA is expected to conclude the review and announce an approval decision by Aug. 30.

It might seem backwards, but the companies filed enasidenib with the FDA before disclosing publicly all the clinical data submitted to regulators. The last time Celgene and Agios presented data from the enasidenib clinical trial was December 2015.

The new trial results disclosed for the first time Wednesday night:

Among 176 patients with relapsed/refractory AML, enasidenib demonstrated an overall response rate of 40%, including a complete remission rate of 19%. The median duration of response was 5.8 months.

When this trial was last presented in December 2015, there were 159 patients treated. The overall response rate to enasidenib was 37%, including a complete remission rate of 18%. The median duration of response was 6.9 months.

New question: Is the shorter duration of response shown today with enasidenib a potential cause for concern with FDA?

The full text of the new enasidenib ASCO research abstract is below. Additional data from the enasidenib will be presented at the ASCO annual meeting.

Abstract #7004

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

JUST UPDATED – TheStreet’s Biotech Bible! Before you invest one single dime in any biotech stock you have got to KNOW WHAT YOU ARE BUYING! Get THE most comprehensive text covering the 186 biotech companies that have gone public since 2013! There’s nothing else like it for digging into this highly speculative group of stocks. Grab a FREE copy today!

Background: Recurrent mutations in isocitrate dehydrogenase 2 (mIDH2) occur in 8-15% of AML pts. mIDH2 proteins synthesize an oncometabolite, 2-hydroxyglutarate (2HG), causing DNA and histone hypermethylation and blocked myeloid differentiation. Enasidenib (AG-221) is an oral, selective, small-molecule inhibitor of mIDH2 protein. Methods: This phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clinical activity of enasidenib in pts with mIDH2 myeloid malignancies. Safety for all pts and efficacy outcomes for R/R AML pts from the phase 1 dose-escalation and expansion phases are reported. Results: In all, 239 pts received enasidenib. In the dose-escalation (n=113), the MTD was not reached at doses up to 650 mg daily. Median 2HG reductions from baseline were 92%, 90%, and 93% for pts receiving <100 mg, 100 mg, and >100 mg daily, respectively. Enasidenib 100 mg QD was chosen for the expansion phase (n=126) based on PK/PD profiles and demonstrated efficacy. Median number of enasidenib cycles was 5 (range 1-25). Grade 3-4 drug-related investigator reported AEs included indirect hyperbilirubinemia (12%) and IDH-inhibitor-associated differentiation syndrome (ie, retinoic acid syndrome; 7%). For R/R AML pts, overall response rate (ORR) was 40.3%, including 34 (19.3%) complete remissions (CR; Table). Response was associated with cellular differentiation, typically with no evidence of aplasia. Median overall survival (OS) for R/R AML pts was 9.3 months (mos). For pts who attained CR, OS was 19.7 mos. Pts who had received ≥2 prior AML regimens (n=94; 53%) had median OS of 8.0 mos. Conclusions: Enasidenib was well tolerated, induced CRs, and was associated with OS of >9 mos in pts who had failed prior AML therapies. Differentiation of myeloblasts, not cytotoxicity, appears to drive the clinical efficacy of enasidenib.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: